OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs. This €10 million payment reinforces the Company’s financial visibility until Q3 2022. OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the......